Retinal Disease

Topline results from an open-label safety study investigating ONS-5010/Lytenava in the treatment of retinal diseases showed no unexpected safety results, according to a press release from Outlook Therapeutics.

Clinical trials have clearly laid out treatment protocols, usually with monthly treatment intervals, and the subjects tend to be compliant and motivated for the study visits. In the real world, life gets in the way.

The best source of evidence to base one’s clinical decisions on is a well-designed prospective randomized masked controlled clinical trial.

The COVID-19 pandemic has forced changes to practice routines that, in many cases, have come at the expense of efficiency.

In conjunction with the annual ASRS Preferences and Trends survey, retina specialists in Asia-Pacific, Africa and Middle East, Central-South America and Europe were invited to participate in the Global Trends in Retina Survey.

Angiogenesis required the coordinated function of regulatory and effector proteins, including the VEGF, TIE, angiopoietin and integrin families, Peter K. Kaiser, MD, of the Cole Eye Institute at Cleveland Clinic, said in a video interview.

At the virtual Euretina congress, Francesco Bandello, MD, speaks about faricimab, a drug that combines anti-VEGF and Ang-2-blocking properties.

The most common drugs injected into the vitreous to treat posterior segment disease are steroids and anti-VEGF medication. To keep it simple, I will use trade names when available.

The FDA has granted a fourth orphan drug designation for OCU400 to treat PDE6B gene mutation-associated retinal diseases, according to an Ocugen press release.

In this video from the virtual American Society of Retina Specialists meeting, Peter K. Kaiser, MD, discusses AXT107, a synthetic peptide designed to treat wet age-related macular degeneration and macular edema.